QUICK ANSWER · AEO / GEO
Cardarine, GW501516 and GW1516 identify an experimental PPAR-beta/delta agonist, not a SARM or anabolic steroid. Short controlled human studies reported lipid-biomarker changes but did not establish cardiovascular-event reduction, fat loss, endurance benefit or long-term safety. Animal studies report tumour-promoting signals in susceptible models; these do not quantify human incidence but preclude a proven-safety claim. WADA 2026 prohibits GW501516 at all times as a metabolic modulator.
ENTITY FACTS
What should readers identify first?
What remains unknown?
Insufficient data in the current dataset
What limits these conclusions?
- PPAR-delta agonist ≠ SARM; lipid biomarker change ≠ cardiovascular benefit; mouse tumour signal ≠ quantified human incidence but cannot be dismissed as proof of safety
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
FAQ · ANSWER ENGINE
Frequently asked questions
What is Cardarine / GW501516?
Cardarine / GW501516 is described pharmacologically as Experimental PPAR-beta/delta agonist; not a SARM. Cardarine, GW501516 and GW1516 identify an experimental PPAR-beta/delta agonist, not a SARM or anabolic steroid. Short controlled human studies reported lipid-biomarker changes but did not establish cardiovascular-event reduction, fat loss, endurance benefit or long-term safety. Animal studies report tumour-promoting signals in susceptible models; these do not quantify human incidence but preclude a proven-safety claim. WADA 2026 prohibits GW501516 at all times as a metabolic modulator.
Does Cardarine / GW501516 have strong evidence?
PrimeCoreBio records Evidence Grade B. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is Cardarine / GW501516 approved everywhere?
No global conclusion should be inferred. PrimeCore Class B must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.